Portal de investigación
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Daver, Naval Guastad
- DeAngelo, Daniel J.
- Wang, Eunice S.
- Todisco, Elisabetta
- Tarella, Corrado
- Martinelli, Giovanni
- Erba, Harry Paul
- Deconinck, Eric
- Sweet, Kendra L.
- Walter, Roland B.
- Levy, Moshe Yair
- Pemmaraju, Naveen
- Lane, Andrew A.
- Rizzieri, David
- Konopleva, Marina
- Sloss, Callum Mortimer
- Wang, Jiuzhou
- Malcolm, Kara E.
- Zweidler-McKay, Patrick A.
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Daver,NG,Montesinos,P,DeAngelo,DJ,Wang,ES,Todisco,E,Tarella,C,Martinelli,G et al. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2020. ELECTR NETWORK-MAY 29-31. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA:AMER SOC CLINICAL ONCOLOGY. 2020.